SAGE Sage Therapeutic Com

$-0.34 (-0.78%)

SAGE Stock Analysis Overview

What this means: InvestorsObserver gives Sage Therapeutic Com (SAGE) an overall rank of 35, which is below average. Sage Therapeutic Com is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 35 means that 65% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full SAGE report

Sage Therapeutic Com (SAGE) Analyst Forecast

Next 12 months ➝Current Price$43.0152-week High$193.5652-week Low$25.01MEAN$69.61+61.85%HIGH$143.00+232.48%LOW$35.00-18.62%
  • Last Price$43.01
  • Previous Close$43.35
  • Change $-0.34
  • Open$44.04
  • Volume649,337
  • Avg. Volume (100-day)1,168,770
  • Market Capitalization$2B
  • Days Range $42.92 - $44.80
  • 52-week Range $25.01 - $193.56
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS-12.45
  • Earnings Date08/04/2020
  • SectorHealthcare
  • IndustryBiotechnology
  • Avg. Analyst Rec.
  • Beta0.996
  • PEG Ratio
  • Volatility0.63
  • Average True Range0.06
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development.